Helicos Lowers Expectations

Helicos Biosciences Corp., a Cambridge, Mass.-based DNA sequencing company, has reduced its IPO offering range from $13-$15 per share to $10-$11 per share. It still plans to offer 5.4 million common shares, and to trade on the Nasdaq under ticker symbol HLCS. UBS is serving as lead underwriter. The company has raised around $67 million in VC funding from firms like Flagship Ventures (20.6% pre-IPO stake), Atlas Venture (17.6%), Highland Capital Partners (17.6%), MPM Capital (12.9%) and Versant Ventures (9.9%). www.helicosbio.com